Looking beyond Lucentis on the management of macular degeneration.

PURPOSE

Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. In the past decade, AMD research has improved our understanding of the pathogenesis of the condition. There is no doubt that anti-VEGF therapies will play a major role in the reduction of blindness, but it needs close monitoring and frequent treatments. In this review we summarise the key pathophysiology of the condition and some of the new treatment strategies under development.

METHODS

Literature review.

RESULTS

Oxidative stress, inflammation, hypoxia, and angiogenesis are key pathophysiological processes in AMD, this diversity has provided a variety of possible areas amenable to modification to enhance the treatment options for AMD.